CL2004001165A1 - COMPOUNDS DERIVED FROM N-SUBSTITUTED ANILINE AND DIFENYLAMINE; INHIBITORS OF PDE4 ENZYMES; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF COGNITIVE DISORDERS. - Google Patents
COMPOUNDS DERIVED FROM N-SUBSTITUTED ANILINE AND DIFENYLAMINE; INHIBITORS OF PDE4 ENZYMES; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF COGNITIVE DISORDERS.Info
- Publication number
- CL2004001165A1 CL2004001165A1 CL200401165A CL2004001165A CL2004001165A1 CL 2004001165 A1 CL2004001165 A1 CL 2004001165A1 CL 200401165 A CL200401165 A CL 200401165A CL 2004001165 A CL2004001165 A CL 2004001165A CL 2004001165 A1 CL2004001165 A1 CL 2004001165A1
- Authority
- CL
- Chile
- Prior art keywords
- difenylamine
- inhibitors
- treatment
- pharmaceutical composition
- cognitive disorders
- Prior art date
Links
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- -1 N-SUBSTITUTED ANILINE Chemical class 0.000 title 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/88—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/92—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26265101P | 2001-01-22 | 2001-01-22 | |
US26719601P | 2001-02-08 | 2001-02-08 | |
US30614001P | 2001-07-19 | 2001-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2004001165A1 true CL2004001165A1 (en) | 2005-04-15 |
Family
ID=27401532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200401165A CL2004001165A1 (en) | 2001-01-22 | 2004-05-20 | COMPOUNDS DERIVED FROM N-SUBSTITUTED ANILINE AND DIFENYLAMINE; INHIBITORS OF PDE4 ENZYMES; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF COGNITIVE DISORDERS. |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1353907A2 (en) |
JP (1) | JP4223287B2 (en) |
KR (1) | KR100856622B1 (en) |
CN (1) | CN100378075C (en) |
AU (1) | AU2002303078B2 (en) |
BG (1) | BG108003A (en) |
BR (1) | BR0206943A (en) |
CA (1) | CA2435847A1 (en) |
CL (1) | CL2004001165A1 (en) |
CZ (1) | CZ20031986A3 (en) |
EE (1) | EE05362B1 (en) |
HK (1) | HK1066215A1 (en) |
HR (1) | HRP20030662A2 (en) |
HU (1) | HUP0302793A3 (en) |
IL (1) | IL156958A0 (en) |
MA (1) | MA25996A1 (en) |
MX (1) | MXPA03006519A (en) |
NO (1) | NO329548B1 (en) |
NZ (1) | NZ527081A (en) |
PL (1) | PL373301A1 (en) |
SK (1) | SK9152003A3 (en) |
WO (1) | WO2002074726A2 (en) |
YU (1) | YU57603A (en) |
ZA (1) | ZA200305623B (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153871B2 (en) | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
CA2438480C (en) * | 2001-02-14 | 2011-05-03 | Abbott Laboratories | Glucocorticoid receptor modulators |
RU2354648C2 (en) | 2002-07-19 | 2009-05-10 | Мемори Фармасьютиклз Корпорейшн | 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
JP2006504656A (en) * | 2002-07-19 | 2006-02-09 | メモリー・ファーマシューティカルズ・コーポレイション | Phosphodiesterase 4 inhibitors comprising N-substituted anilines and diphenylamine analogues |
KR20050075430A (en) | 2002-11-19 | 2005-07-20 | 메모리 파마슈티칼스 코포레이션 | Phosphodiesterase 4 inhibitors |
US20060040981A1 (en) * | 2002-11-22 | 2006-02-23 | Daniel Dube | Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
PT1578740E (en) * | 2002-12-27 | 2007-05-31 | Lundbeck & Co As H | 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system |
FR2856595B1 (en) * | 2003-06-27 | 2008-05-30 | Exonhit Therapeutics Sa | METHODS AND COMPOSITIONS FOR TREATING COGNITIVE DEFICITS. |
JP2007504201A (en) | 2003-09-05 | 2007-03-01 | アルタナ ファルマ アクチエンゲゼルシャフト | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
CA2571133C (en) | 2004-07-15 | 2011-04-19 | Japan Tobacco Inc. | Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
WO2006049968A1 (en) * | 2004-10-28 | 2006-05-11 | Merck & Co., Inc. | Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
US8017633B2 (en) | 2005-03-08 | 2011-09-13 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
AU2006257863A1 (en) * | 2005-06-10 | 2006-12-21 | F. Hoffmann-La Roche Ag | Trisubstituted amines as phosphodiesterase 4 inhibitors |
AR057455A1 (en) * | 2005-07-22 | 2007-12-05 | Merck & Co Inc | INHIBITORS OF HIV REVERSE TRANSCRIPTASE AND PHARMACEUTICAL COMPOSITION |
US7906508B2 (en) | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
EP2110375A1 (en) * | 2008-04-14 | 2009-10-21 | CHIESI FARMACEUTICI S.p.A. | Phosphodiesterase-4 inhibitors belonging to the tertiary amine class |
US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
JP5542059B2 (en) * | 2008-10-09 | 2014-07-09 | 国立大学法人 岡山大学 | Antiallergic agent containing RXR agonist as active ingredient |
MX2019008390A (en) * | 2009-06-12 | 2019-09-09 | Abivax | Compounds useful for treating cancer. |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
CN113004249A (en) | 2009-06-12 | 2021-06-22 | Abivax公司 | Compounds for the treatment of premature aging and especially premature aging |
EP2533780B1 (en) | 2010-02-12 | 2017-08-23 | AskAt Inc. | 5-ht4 receptor agonists for the treatment of dementia |
US9550763B2 (en) | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
CN102603676B (en) * | 2012-02-20 | 2014-02-12 | 徐江平 | Phosphodiesterase 4 inhibitor capable of avoiding vomiting reaction |
CN104136021B (en) * | 2012-03-14 | 2016-04-20 | 中国中化股份有限公司 | Substituted diphenylamine aminated compounds is as the application preparing antitumor drug |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
EP3016656B1 (en) | 2013-07-05 | 2021-09-08 | Abivax | Bicyclic compounds useful for treating diseases caused by retroviruses |
EP3033082B1 (en) | 2013-08-16 | 2021-06-16 | Universiteit Maastricht | Treatment of cognitive impairment with pde4 inhibitor |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994027971A1 (en) * | 1993-05-27 | 1994-12-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines |
JPH07206789A (en) * | 1993-09-01 | 1995-08-08 | Taisho Pharmaceut Co Ltd | Production of combretastatin analog compound |
US5591776A (en) * | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
FR2729142A1 (en) * | 1995-01-06 | 1996-07-12 | Smithkline Beecham Lab | New heterocyclic amine derivs. |
EP0994100B1 (en) * | 1997-06-24 | 2006-08-30 | Nikken Chemicals Company, Limited | 3-anilino-2-cycloalkenone derivates |
CA2373990C (en) * | 1999-05-21 | 2007-05-08 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
EP1116711B1 (en) * | 1999-12-18 | 2005-12-14 | Wella Aktiengesellschaft | 2-aminoalkyl-1,4-diaminobenzene derivatives and dye composition containing these compounds |
-
2002
- 2002-01-22 CN CNB028070100A patent/CN100378075C/en not_active Expired - Fee Related
- 2002-01-22 KR KR1020037009624A patent/KR100856622B1/en not_active IP Right Cessation
- 2002-01-22 MX MXPA03006519A patent/MXPA03006519A/en active IP Right Grant
- 2002-01-22 NZ NZ527081A patent/NZ527081A/en unknown
- 2002-01-22 YU YU57603A patent/YU57603A/en unknown
- 2002-01-22 SK SK915-2003A patent/SK9152003A3/en unknown
- 2002-01-22 PL PL02373301A patent/PL373301A1/en not_active Application Discontinuation
- 2002-01-22 AU AU2002303078A patent/AU2002303078B2/en not_active Ceased
- 2002-01-22 BR BR0206943-1A patent/BR0206943A/en not_active Application Discontinuation
- 2002-01-22 EE EEP200300347A patent/EE05362B1/en not_active IP Right Cessation
- 2002-01-22 WO PCT/US2002/001508 patent/WO2002074726A2/en active Application Filing
- 2002-01-22 EP EP02731078A patent/EP1353907A2/en not_active Withdrawn
- 2002-01-22 IL IL15695802A patent/IL156958A0/en unknown
- 2002-01-22 CA CA002435847A patent/CA2435847A1/en not_active Abandoned
- 2002-01-22 JP JP2002573735A patent/JP4223287B2/en not_active Expired - Fee Related
- 2002-01-22 CZ CZ20031986A patent/CZ20031986A3/en unknown
- 2002-01-22 HU HU0302793A patent/HUP0302793A3/en unknown
-
2003
- 2003-07-18 BG BG108003A patent/BG108003A/en unknown
- 2003-07-21 NO NO20033288A patent/NO329548B1/en not_active IP Right Cessation
- 2003-07-21 ZA ZA2003/05623A patent/ZA200305623B/en unknown
- 2003-07-22 MA MA27246A patent/MA25996A1/en unknown
- 2003-08-20 HR HR20030662A patent/HRP20030662A2/en not_active Application Discontinuation
-
2004
- 2004-05-20 CL CL200401165A patent/CL2004001165A1/en unknown
- 2004-11-17 HK HK04109061A patent/HK1066215A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2435847A1 (en) | 2002-09-26 |
MXPA03006519A (en) | 2004-10-15 |
NO20033288D0 (en) | 2003-07-21 |
BG108003A (en) | 2004-09-30 |
CZ20031986A3 (en) | 2003-12-17 |
JP4223287B2 (en) | 2009-02-12 |
WO2002074726A2 (en) | 2002-09-26 |
WO2002074726A3 (en) | 2003-03-13 |
SK9152003A3 (en) | 2004-04-06 |
AU2002303078B2 (en) | 2007-08-30 |
CN100378075C (en) | 2008-04-02 |
HUP0302793A3 (en) | 2006-01-30 |
PL373301A1 (en) | 2005-08-22 |
EE200300347A (en) | 2003-12-15 |
MA25996A1 (en) | 2003-12-31 |
BR0206943A (en) | 2006-01-24 |
NZ527081A (en) | 2006-03-31 |
EP1353907A2 (en) | 2003-10-22 |
KR20040064606A (en) | 2004-07-19 |
EE05362B1 (en) | 2010-12-15 |
HRP20030662A2 (en) | 2005-06-30 |
JP2005507365A (en) | 2005-03-17 |
HK1066215A1 (en) | 2005-03-18 |
KR100856622B1 (en) | 2008-09-03 |
ZA200305623B (en) | 2005-01-26 |
NO329548B1 (en) | 2010-11-08 |
HUP0302793A2 (en) | 2003-11-28 |
CN1498211A (en) | 2004-05-19 |
NO20033288L (en) | 2003-09-22 |
YU57603A (en) | 2006-08-17 |
IL156958A0 (en) | 2004-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2004001165A1 (en) | COMPOUNDS DERIVED FROM N-SUBSTITUTED ANILINE AND DIFENYLAMINE; INHIBITORS OF PDE4 ENZYMES; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF COGNITIVE DISORDERS. | |
BRPI0312649A2 (en) | compounds, pharmaceutical compositions containing them, and processes of use therefor. | |
DK1399444T3 (en) | New heterocyclic compounds, processes for the preparation of same and their use as drugs, especially as antibacterial agents | |
EA200700489A1 (en) | NEW BENZO-CONDENSED HETEROARYL SULFAMIDE DERIVATIVES, USEFUL AS ANTI-CONVOLTIVE AGENT | |
DK1888584T3 (en) | Tricyclic 1,6-dihydro-1,3,5,6-tetraaza-as-indacene-based compounds and pharmaceutical compositions comprising the same as inhibitors of IKK enzyme activity | |
DE602004008105D1 (en) | 42-O-ALKOXYALKYLRAPAMYCIN DERIVATIVES AND COMPOSITIONS CONTAINING THEREOF | |
CL2003002353A1 (en) | COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC | |
HUP0401665A3 (en) | Alfa and beta-form crystal of an aminothiazolyl acetanilide derivative, their use and pharmaceutical compositions containing them | |
ECSP055701A (en) | NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME | |
DE60233718D1 (en) | WATER-BASED HYDROPHOBIC AGENT FOR THE TREATMENT OF SUBSTRATES | |
DE60235083D1 (en) | SUBSTITUTED TETRACYCLIN COMPOUNDS FOR THE TREATMENT OF MALARIA | |
AP2005003424A0 (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them. | |
WO2006078287A3 (en) | Pde4b inhibitors and uses therefor | |
PT1392292E (en) | PIRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | |
DK1448195T3 (en) | N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation | |
DK1776349T3 (en) | 2-Amino-Puinazoline Derivatives Usable as Inhibitors of Beta-Secretase (BACE) | |
DE602004014296D1 (en) | Chromium-free agent for the treatment of metal surfaces | |
DE60314013D1 (en) | 2- (1H-INDAZOL-6-YLAMINO) BENZAMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF OPHTHALMIC ILLNESSES | |
NO20035025L (en) | Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity. | |
DK1448205T3 (en) | Combinations for the treatment of immuno-inflammatory diseases | |
PT1411926E (en) | INTEGRINE INHIBITORS FOR THE TREATMENT OF OPHTHALMIC DISEASES | |
DE60218451D1 (en) | 15-KETO-PROSTAGLANDINE FOR THE TREATMENT OF DRUG-INDUCED OBSTIPATION | |
NO20033803D0 (en) | Carbamate for the treatment of movement disorders | |
BRPI0411864A (en) | combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
CY1109975T1 (en) | PARA-ALKYL-SUBSTITUTED N-(4-HYDROXY-3-METHOXY-BENZYL) AMIDIA AMINAMIC ACID AND THEIR USE FOR PARASKA |